Latest News

Oral peptide drugs move beyond injections, bringing targeted psoriasis therapy like icotrokinra and reshaping dermatology’s treatment options.

Phase 1/2 data from RESET-Myositis, RESET-SSc, and RESET-SLE presented at EULAR 2026 show durable immunomodulator-free responses and a consistent safety profile across indications.

Medicus Pharma advances microneedle doxorubicin therapy, which aims to clear multiple Gorlin Syndrome BCC lesions.

Experts recommend routine genital assessment as part of comprehensive skin exams rather than relying on patient-initiated reporting of this sensitive manifestation.

This review of the latest dermatological studies includes insights on PeakPASI in psoriasis severity, the future of digital derm lectures, negative pressure wound therapy, and more.

New IND pushes QRX003 toward first targeted therapy for peeling skin syndrome, with early pediatric results showing rapid healing and no safety issues.

Discover how oral GliSODin delivers SOD to boost skin defense, enhance retinoids, and reduce UV damage and dark spots—backed by clinical trials.

Unlock hidden dermatology revenue by tracking retention drop-offs, procedure sequencing, and device utilization—before collections reveal the leaks.

Unlike approved AD biologics and JAK inhibitors targeting specific cytokine pathways, GX-03 is designed to modulate inflammatory signaling locally within the skin microenvironment.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Can misting hypochlorous acid every day improve skin, or is it just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

This month’s podcasts highlight the latest clinical insights, emerging therapies, and evolving conversations shaping dermatology practice.